Recovery of *Streptococcus iniae* from Diseased Fish Previously Vaccinated with a *Streptococcus* Vaccine

GILAD BACHRACH,1 AMIR ZLOTKIN,2 AVSHALOM HURVITZ,3 DONALD L. EVANS,4 AND AVI ELDAR5*

Department of Oral Biology, Faculty of Dental Medicine,1 and Department of Clinical Microbiology,2 The Hebrew University-Hadassah Medical School, Jerusalem 91120, Dan Fish Farms, Kibbutz Dan, Upper Galilee 12245,3 and Department of Poultry and Fish Diseases, The Kimron Veterinary Institute, Bet Dagan 50250,5 Israel, and Department of Medical Microbiology and Parasitology, College of Veterinary Medicine, University of Georgia, Athens, Georgia 306024

Received 20 February 2001/Accepted 31 May 2001

*Streptococcus iniae* was recovered from diseased rainbow trout (*Oncorhynchus mykiss*, Walbaum) previously vaccinated against streptococcosis. PCR and serological methods indicate the presence of a new serotype in the diseased fish.

The fish pathogen *Streptococcus iniae* (11) is endemic in various parts of the world, including Israel (6) and North America (10). *S. iniae* infection of rainbow trout (*Oncorhynchus mykiss*) produces a disease which substantially affects the brain, with only minor pathological changes in other organs (4). Recently, *S. iniae* has been isolated from diseased humans suffering from cellulitis, meningitis, and bacteremias, indicating a threat to public health (16).

A specific *S. iniae* vaccine became available in 1995. From 1995 to 1997, all Israeli trout farms in the Upper Galilee, (which share water reservoirs) routinely vaccinated their entire stocks (roughly 3 million fish/year), reducing *S. iniae*-related mortalities from 50% annually to less than 5% (5). However, massive new outbreaks of the disease were recorded in 1997. Unlike the previous pathological manifestations, diseased fish exhibited multisystem organ involvement and diffuse internal hemorrhages. Brains samples were collected from diseased fish and streaked on Columbia agar base (Difco) supplemented with 5% (vol/vol) defibrinated sheep blood. Beta-hemolytic gram-positive cocci were detected following an incubation of 24 to 48 h at 24°C. Conventional identification schemes (API 20 STREP; BioMerieux SA, Marcy l’Etoie, France) suggested that all isolates (of 100 collected over 24 months) were *S. iniae*. The new isolates, unlike the previous isolates, were shown to be arginine dehydrolase (ADH) negative. Definitive identification was accomplished by PCR, using *S. iniae* 16S rDNA-specific primers (Zlotkin et al. [17]), which revealed the 300-bp *S. iniae*-specific PCR product in all isolates.

Six early ADH-positive isolates collected in 1989 (Dan 1), 1991 (Dan 3 and Dan 4), 1992 (Dan 15 and Dan 16), and 1995 (Dan 35) [collected prior to the vaccination program] and seven recent ADH-negative-isolates obtained from vaccinated fish in 1997 (KFP 173), 1998 (KFP 186), 1999 (KFP 198, KFP 199, and KFP 206), and 2000 (KFP 400 and KFP 404) were randomly taken for further characterization.

Primers U-1 and U-1500 (*Escherichia coli* 16S rDNA sequence [GenBank accession no. J01859], positions 7 to 27 and 1516 to 1540, respectively) were used for 16S rDNA amplification and sequencing of isolates Dan 1, Dan 4, Dan 35, KFP 173, KFP 186, and KFP 198 and *S. iniae* ATCC 29178 (isolated in 1976 from a diseased Amazonian dolphin (11)). The rDNA sequence analyses confirmed that the six isolates were *S. iniae*. All had an identical sequence (GenBank accession no. AF335573) and differed from that of *S. iniae* ATCC 29178 (GenBank accession no. AF335572) in six bases (99.6% homology). *EcoRI* and *HindIII* digests of DNAs extracted from early and recent isolates resulted in identical restriction fragment length polymorphism ribotype patterns (data not shown), indicating that all isolates cluster in the Israeli *S. iniae* rank (6). The use of additional endonucleases (*PvuI* or *KpnI*) did not provide strain-to-strain differentiation (data not shown).

The random amplified polymorphic DNA (RAPD) technique (Fig. 1) was used to distinguish early from recent isolates. Primer p14 (5’GATCAAGTCC), previously proven useful for discrimination among group A streptococcol strains, was used (Neeman et al. [8]). All early (1991 to 1995) isolates produced a band with an estimated length of 750 bp. No such band was found in the PCR product of the recent isolates (Fig. 1).

Hyperimmune sera for serological differentiation were obtained by three monthly immunizations of rainbow trout with formalin-fixed *S. iniae* Dan 1 or *S. iniae* KFP 173 bacterin (5). Specific group antigens were extracted by exposure of the bacteria to 0.2 N HCl for 10 min at 100°C (7), and immunodiffusion tests were performed by the agar-gel method of Ouchterlony (9). As shown in Fig. 2 and 3, sera against *S. iniae* Dan 1 reacted with all early isolates; sera against *S. iniae* KFP 173 reacted with all recent isolates. While sera against Dan 1 failed to recognize recent strains, sera against KFP 173 recognized early strains in a manner that indicates partial identity (Fig. 3).

Partial immunological cross-recognition between early and recent isolates was also demonstrated in agglutination tests, in which 50-μl samples of formalin-killed *S. iniae* Dan 1 and KFP
173, diluted to an optical density of 0.8 at 540 nm, were reacted with serial dilutions of specific sera. Sera raised against *S. iniae* Dan 1 precipitated the early isolates at dilutions of up to 1:2,560 but precipitated none of the recent ones. However, sera raised against *S. iniae* KFP 173 recognized all of the recent strains (titers of 1:2,560), as well as all of the early strains, which were precipitated at low serum dilutions (1:20). Recent *S. iniae* isolates were therefore designated serotype II strains, while early *S. iniae* strains were designated serotype I strains.

Contrary to eradication schemes, vaccination of large stocks cannot eliminate the pathogen. We have previously shown that, while vaccination drastically reduced mortality, the pathogen still remained in some of the fish or in the environment (5). As a consequence of the selective pressure induced by the vaccination, a second serotype appears to have taken over. The RAPD analysis (Fig. 1) supports this assumption, demonstrating that a shift from a stable environment containing *S. iniae* serotype I isolates to an environment containing serotype II isolates has occurred.

Serological tests indicating a shift in the capsular composition provide further support to the assumption that selection favoring the emergence of a vaccine-resistant serotype has occurred (Fig. 2 and 3). Capsular polysaccharides have long been recognized as a major virulence factor of many streptococci. The onset of disease caused by group B streptococci is strictly dependent on the capsular type. The vast majority of neonatal group B streptococcal meningitis cases and the majority of cases of late-onset disease are related to type III strains (3, 14). But the classic example is that of *Streptococcus pneumoniae*, in which differences between serotypes also result in adverse terms of activation of the alternative pathway of complement (12), deposition and degradation of complement components on the capsule (2), resistance to phagocytosis, and ability to induce antibodies (15). In the disease caused by *S. pneumoniae*, it has been shown that protection is related to anticapsular antibodies present in serum (1, 13).

To summarize, the long-term massive vaccination of rainbow trout against serotype I resulted in an outbreak of serotype II, which is able to evade the protective response elicited by vaccination with type I strains.

We thank Shira Yaron for her assistance.

This work was supported by a joint American-Israeli grant (BARD IS-2727-96R).

REFERENCES.